# Curis Inc. (CRIS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $6M  
**Price:** $0.42 (-2.59%)

> Curis Inc. is a biotechnology company focused on discovering and developing drug candidates for treating human cancers. The company's lead program centers on emavusertib (CA-4948), an orally available small molecule inhibitor targeting IRAK4 and FLT3, currently in clinical development for hematologic malignancies including acute myeloid leukemia, myelodysplastic syndromes, and primary central nervous system lymphoma, particularly in patients with relapsed or refractory disease. Emavusertib has received Orphan Drug Designation from the FDA and European Commission, recognizing its potential for treating rare blood cancers. Curis pursues combination therapeutic approaches, pairing emavusertib with established treatments like BTK inhibitors, venetoclax, and azacitidine across multiple indications. The company's pipeline also includes additional candidates such as fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes. Curis advances its programs through clinical collaborations, key opinion leader engagement, and strategic licensing partnerships, including an exclusive license to emavusertib from Aurigene Discovery Technologies Limited. Founded in 2000 and headquartered in Lexington, Massachusetts, Curis operates as an early-stage clinical biotechnology company seeking to address significant unmet needs in oncology.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $9M | — | -$6M | -$8M | — |
| 2024 | $11M | — | -$45M | -$43M | — |
| 2023 | $10M | — | -$48M | -$47M | — |
| 2022 | $10M | — | -$53M | -$57M | — |
| 2021 | $11M | — | -$42M | -$45M | — |
| 2020 | $11M | — | -$25M | -$30M | — |
| 2019 | $10M | — | -$24M | -$32M | — |
| 2018 | $10M | — | -$29M | -$33M | — |
| 2017 | $10M | — | -$50M | -$53M | — |
| 2016 | $8M | — | -$58M | -$60M | — |
| 2015 | $8M | — | -$56M | -$59M | — |
| 2014 | $10M | — | -$16M | -$19M | — |
| 2013 | $15M | — | -$9M | -$12M | — |
| 2012 | $17M | — | -$19M | -$16M | — |
| 2011 | $15M | — | -$7M | -$10M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $20M | $15M | $5M | $5M | — |
| 2024 | $41M | $47M | -$6M | $20M | — |
| 2023 | $77M | $58M | $20M | $27M | — |
| 2022 | $109M | $62M | $47M | $20M | — |
| 2021 | $162M | $72M | $91M | $40M | — |
| 2020 | $204M | $74M | $131M | $130M | $334,000 |
| 2019 | $35M | $69M | -$34M | $15M | — |
| 2018 | $37M | $42M | -$4M | $24M | $29M |
| 2017 | $74M | $50M | $24M | $38M | $36M |
| 2016 | $58M | $28M | $29M | $26M | $15M |
| 2015 | $95M | $30M | $65M | $33M | $20M |
| 2014 | $63M | $33M | $30M | $8M | $23M |
| 2013 | $81M | $35M | $45M | $10M | $28M |
| 2012 | $70M | $36M | $34M | $13M | $30M |
| 2011 | $48M | $8M | $40M | $15M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$27M | — | — |
| 2024 | -$40M | — | — |
| 2023 | -$38M | — | -$38M |
| 2022 | -$54M | $416,000 | -$55M |
| 2021 | -$38M | — | -$38M |
| 2020 | -$26M | $677,000 | -$26M |
| 2019 | -$26M | $41,000 | -$26M |
| 2018 | -$30M | $85,000 | -$30M |
| 2017 | -$48M | $188,000 | -$49M |
| 2016 | -$36M | $329,000 | -$36M |
| 2015 | -$30M | $48,000 | -$30M |
| 2014 | -$17M | $92,000 | -$17M |
| 2013 | -$10M | $153,009 | -$10M |
| 2012 | -$15M | $104,975 | -$15M |
| 2011 | -$5M | $260,405 | -$5M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CRIS)